

## SAFETY DATA SHEETS

**This SDS packet was issued with item:**

078801778

**The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).**

078074070

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

**SECTION 1. IDENTIFICATION**

Product name : Orbifloxacin Liquid Formulation

**Manufacturer or supplier's details**

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Reproductive toxicity : Category 2

Specific target organ toxicity : Category 2 (Eye)  
- repeated exposure (Oral)

**GHS label elements**

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.  
H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe mist or vapors.  
P280 Wear protective gloves, protective clothing, eye protection and face protection.  
**Response:**  
P308 + P313 IF exposed or concerned: Get medical attention.  
**Storage:**  
P405 Store locked up.

**Orbifloxacin Liquid Formulation**

Version 4.9      Revision Date: 04/04/2023      SDS Number: 785439-00017      Date of last issue: 10/01/2022  
Date of first issue: 06/28/2016

**Disposal:**

P501 Dispose of contents and container to an approved waste disposal plant.

**Other hazards**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Propylene glycol	57-55-6	$\geq 10 - < 20$
Orbifloxacin	113617-63-3	$\geq 1 - < 5$
Silicon dioxide	7631-86-9	$\geq 1 - < 5$
Lactic acid	50-21-5	$\geq 1 - < 5$
Sodium hydroxide	1310-73-2	$\geq 1 - < 2$

Actual concentration is withheld as a trade secret

**SECTION 4. FIRST AID MEASURES**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Suspected of damaging the unborn child.  
May cause damage to organs through prolonged or repeated exposure if swallowed.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

Unsuitable extinguishing media	:	Dry chemical None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**SECTION 7. HANDLING AND STORAGE**

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not breathe mist or vapors. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin.

---

## Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Propylene glycol	57-55-6	TWA	10 mg/m <sup>3</sup>	US WEEL
Orbifloxacin	113617-63-3	TWA	0.2 mg/m <sup>3</sup> (OEB 2)	Internal
Silicon dioxide	7631-86-9	TWA (Dust)	20 Million particles per cubic foot (Silica)	OSHA Z-3
		TWA (Dust)	80 mg/m <sup>3</sup> / %SiO <sub>2</sub> (Silica)	OSHA Z-3
		TWA	6 mg/m <sup>3</sup> (Silica)	NIOSH REL
Sodium hydroxide	1310-73-2	C	2 mg/m <sup>3</sup>	ACGIH
		C	2 mg/m <sup>3</sup>	NIOSH REL
		TWA	2 mg/m <sup>3</sup>	OSHA Z-1

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Laboratory operations do not require special containment.

#### Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

## Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

circumstance where air purifying respirators may not provide adequate protection.

Hand protection  
Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.  
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : suspension

Color : light brown

Odor : odorless

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure**

Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
---------------------	---	--

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

Acute inhalation toxicity : Acute toxicity estimate: > 200 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: Calculation method

**Components:****Propylene glycol:**

Acute oral toxicity : LD50 (Rat): 22,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 44.9 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity

**Orbifloxacin:**

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg  
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg  
Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg  
Symptoms: Vomiting  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg  
Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg  
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg  
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg  
Application Route: Intravenous

**Silicon dioxide:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 2.08 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhala-



**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

tion toxicity

Acute dermal toxicity : LD50 (Rabbit): &gt; 5,000 mg/kg

**Lactic acid:**Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Remarks: Based on data from similar materialsAcute inhalation toxicity : LC50 (Rat): > 5 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403  
Assessment: Corrosive to the respiratory tract.  
Remarks: Based on data from similar materialsAcute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity  
Remarks: Based on data from similar materials**Sodium hydroxide:**

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

**Skin corrosion/irritation**

Not classified based on available information.

**Product:**Species : Rabbit  
Result : No skin irritation**Components:****Propylene glycol:**Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation**Orbifloxacin:**Species : Rabbit  
Method : Draize Test  
Result : No skin irritation**Silicon dioxide:**Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation**Lactic acid:**Species : Rabbit  
Method : OECD Test Guideline 404

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

Result	: Corrosive after 1 to 4 hours of exposure
Remarks	: Based on data from similar materials

**Sodium hydroxide:**

Result	: Corrosive after 3 minutes or less of exposure
--------	---

**Serious eye damage/eye irritation**

Not classified based on available information.

**Product:**

Species	: Rabbit
Result	: Mild eye irritation

**Components:****Propylene glycol:**

Species	: Rabbit
Result	: No eye irritation
Method	: OECD Test Guideline 405

**Orbifloxacin:**

Species	: Rabbit
Result	: Mild eye irritation
Method	: Draize Test

**Silicon dioxide:**

Species	: Rabbit
Result	: No eye irritation
Method	: OECD Test Guideline 405

**Lactic acid:**

Species	: Chicken eye
Remarks	: Based on data from similar materials
Result	: Irreversible effects on the eye

**Sodium hydroxide:**

Result	: Irreversible effects on the eye
Remarks	: Based on skin corrosivity.

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Product:**

Test Type	: Magnusson-Kligman-Test
-----------	--------------------------

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

Routes of exposure	: Dermal
Species	: Guinea pig
Result	: Not a skin sensitizer.

**Components:****Propylene glycol:**

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Result	: negative

**Orbifloxacin:**

Test Type	: Maximization Test
Routes of exposure	: Dermal
Species	: Guinea pig
Result	: Not a skin sensitizer.

**Lactic acid:**

Test Type	: Buehler Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Result	: negative
Remarks	: Based on data from similar materials

**Sodium hydroxide:**

Test Type	: Human repeat insult patch test (HRIPT)
Routes of exposure	: Skin contact
Result	: negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Propylene glycol:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	--

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative

Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative
----------------------	--

**Orbifloxacin:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
-----------------------	--

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

Result: equivocal

Test Type: Mouse Lymphoma

Result: positive

Test Type: Chromosomal aberration

Test system: Human lymphocytes

Result: positive

Genotoxicity in vivo

: Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Intraperitoneal injection  
Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat

Cell type: Liver cells

Application Route: Oral

Result: negative

Germ cell mutagenicity -  
Assessment

: Weight of evidence does not support classification as a germ  
cell mutagen.

**Silicon dioxide:**

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Genotoxicity in vivo

: Test Type: Mutagenicity (in vivo mammalian bone-marrow  
cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Lactic acid:**

Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative  
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

**Components:****Propylene glycol:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	2 Years
Result	:	negative

**Orbifloxacin:**

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	200 mg/kg body weight
Result	:	negative

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	200 mg/kg body weight
Result	:	negative

**Silicon dioxide:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	103 weeks
Result	:	negative

**Lactic acid:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	2 Years
Result	:	negative
Remarks	:	Based on data from similar materials

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****Propylene glycol:**

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study
		Species: Mouse
		Application Route: Ingestion

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Orbifloxacin:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity Parent: NOAEL: 50 mg/kg body weight  
Early Embryonic Development: NOAEL: 50 mg/kg body weight  
Result: No adverse effects.

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Embryo-fetal toxicity.: LOAEL: 333 mg/kg body weight  
Result: No teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 20 mg/kg body weight  
Embryo-fetal toxicity.: NOAEL: 60 mg/kg body weight  
Result: No effects on early embryonic development., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain.

Test Type: Development  
Species: Dog  
Application Route: Oral  
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight  
Result: Effects on postnatal development., Skeletal malformations.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**Silicon dioxide:**

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Lactic acid:**

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Mouse

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

Application Route: Ingestion

Result: negative

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

**Product:**

Target Organs	:	Eye
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Product:**

Species	:	Dog
NOAEL	:	22.5 mg/kg
LOAEL	:	37.5 mg/kg
Application Route	:	Oral
Exposure time	:	30 Days
Symptoms	:	Gastrointestinal disturbance

Species	:	Dog
LOAEL	:	75 mg/kg
Application Route	:	Oral
Exposure time	:	10 Days
Symptoms	:	Salivation, Gastrointestinal disturbance, Vomiting

Species	:	Cat
LOAEL	:	45 mg/kg
Application Route	:	Oral
Exposure time	:	30 Days
Target Organs	:	Eye
Symptoms	:	Salivation, Lachrymation, Gastrointestinal disturbance, Liver disorders

**Components:****Propylene glycol:**

Species	:	Rat, male
NOAEL	:	>= 1,700 mg/kg
Application Route	:	Ingestion
Exposure time	:	2 y

**Orbifloxacin:**

Species	:	Rat
NOAEL	:	20 mg/kg
LOAEL	:	80 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Testis, Liver, Kidney, spleen

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

Species : Mouse  
NOAEL : 80 mg/kg  
LOAEL : 250 mg/kg  
Application Route : Oral  
Exposure time : 3 Months

Species : Juvenile dog  
NOAEL : 50 mg/kg  
LOAEL : 250 mg/kg  
Application Route : Oral  
Exposure time : 14 Days  
Target Organs : Heart, Bone  
Symptoms : Gastrointestinal disturbance  
Remarks : mortality observed

Species : Juvenile dog  
NOAEL : 2 mg/kg  
LOAEL : 3 mg/kg  
Application Route : Oral  
Exposure time : 90 Days  
Target Organs : Bone  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 37.5 mg/kg  
Application Route : Oral  
Exposure time : 30 Days

Species : Cat  
NOAEL : 7.5 mg/kg  
LOAEL : 22.5 mg/kg  
Application Route : Oral  
Exposure time : 1 Months  
Symptoms : Gastrointestinal disturbance

**Silicon dioxide:**

Species : Rat  
NOAEL : 1.3 mg/m<sup>3</sup>  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 13 Weeks

**Lactic acid:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 13 Weeks  
Remarks : Based on data from similar materials

Species : Rat  
LOAEL : 886 mg/kg  
Application Route : Skin contact  
Exposure time : 13 Weeks



**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Orbifloxacin:**

Ingestion : Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash  
Remarks: May cause photosensitization.

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Propylene glycol:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l  
Exposure time: 7 d

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 20,000 mg/l  
Exposure time: 18 h

**Silicon dioxide:**

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 10,000 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l  
Exposure time: 24 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Desmodesmus subspicatus (green algae)): > 10,000 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

NOEC (Desmodesmus subspicatus (green algae)): 10,000 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

**Lactic acid:**

- Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: Based on data from similar materials
- Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials
- NOEC (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials
- Toxicity to microorganisms : EC50: > 10 - 100 mg/l  
Exposure time: 3 h  
Method: OECD Test Guideline 209  
Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Propylene glycol:**

- Biodegradability : Result: Readily biodegradable.  
Biodegradation: 98.3 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F

**Lactic acid:**

- Biodegradability : Result: Not readily biodegradable.  
Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****Propylene glycol:**

- Partition coefficient: n-octanol/water : log Pow: -1.07  
Method: Regulation (EC) No. 440/2008, Annex, A.8

**Lactic acid:**

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

Partition coefficient: n-octanol/water : log Pow: -0.62

**Mobility in soil**

No data available

**Other adverse effects**

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****49 CFR**

Not regulated as a dangerous good

**Special precautions for user**

Not applicable

**SECTION 15. REGULATORY INFORMATION****CERCLA Reportable Quantity**

Components	CAS-No.	Component RQ (lbs)	Calculated product RQ (lbs)
Sodium hydroxide	1310-73-2	1000	100000

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Reproductive toxicity  
Specific target organ toxicity (single or repeated exposure)

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**US State Regulations****Pennsylvania Right To Know**

Water	7732-18-5
Malt Extract	8002-48-0
2-Propenoic acid, 2-methyl-, polymer with methyl 2-methyl-2-propenoate	25086-15-1
Propylene glycol	57-55-6
Orbifloxacin	113617-63-3
Silicon dioxide	7631-86-9
Sodium hydroxide	1310-73-2

**California List of Hazardous Substances**

Silicon dioxide	7631-86-9
Sodium hydroxide	1310-73-2

**California Permissible Exposure Limits for Chemical Contaminants**

Silicon dioxide	7631-86-9
Sodium hydroxide	1310-73-2

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined


IECSC : not determined

---

**SECTION 16. OTHER INFORMATION****Further information**

# Orbifloxacin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

**NFPA 704:****HMIS® IV:**

<b>HEALTH</b>	*	<b>2</b>
<b>FLAMMABILITY</b>		<b>1</b>
<b>PHYSICAL HAZARD</b>		<b>0</b>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	: USA. NIOSH Recommended Exposure Limits
OSHA Z-1	: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
OSHA Z-3	: USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
US WEEL	: USA. Workplace Environmental Exposure Levels (WEEL)
ACGIH / C	: Ceiling limit
NIOSH REL / TWA	: Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
NIOSH REL / C	: Ceiling value not be exceeded at any time.
OSHA Z-1 / TWA	: 8-hour time weighted average
OSHA Z-3 / TWA	: 8-hour time weighted average
US WEEL / TWA	: 8-hr TWA

AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Oth-

**Orbifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/01/2022
4.9	04/04/2023	785439-00017	Date of first issue: 06/28/2016

---

erwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/04/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8